Acta Neurologica Scandinavica最新文献

{"title":"Ocular Symptoms Are Persistent in AChR Antibody-Positive Generalized Myasthenia Gravis: A Single Center Study Quantified by an Ocular Index","authors":"Xicheng Li,&nbsp;Huahua Zhong,&nbsp;Sushan Luo,&nbsp;Chongbo Zhao","doi":"10.1155/ane/5560889","DOIUrl":"https://doi.org/10.1155/ane/5560889","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction/Aims</h3>\u0000 \u0000 <p>Ocular symptoms are prevalent and exacerbate the disease burden among patients with myasthenia gravis (MG). However, their detection and therapeutic strategies are frequently neglected. The aim of this study is to demonstrate the relative burden of ocular symptoms throughout the treatment course of MG.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective, longitudinal registry-based study at Huashan Hospital, Fudan University, involving 93 treatment-naive patients with acetylcholine receptor antibody-positive (AChR+) MG, and collected their clinical manifestations and pharmacological treatment measures. Myasthenia Gravis Ocular Index (MGOI) of Myasthenia Gravis Activities of Daily Living (MG-ADL), quantitative myasthenia gravis (QMG), myasthenia gravis composite (MGC), and Myasthenia Gravis Quality of Life 15-item (MG-QoL-15) at baseline and at the 2-year follow-up, as well as ΔMGOI, the difference between each pair of MGOIs, were calculated. And a subgroup of 46 patients from this cohort with a follow-up duration of 4 years was utilized for long-term validation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The study found that despite a decline in both ocular and nonocular scores, MGOI for MG scales (ΔMGOI-MG-ADL: 0.10 ± 0.35, <i>p</i> &lt; 0.001; ΔMGOI-QMG: 0.04 ± 0.27, <i>p</i> &gt; 0.05; ΔMGOI-MGC: 0.15 ± 0.35, <i>p</i> &lt; 0.001; ΔMGOI-QoL-15: 0.07 ± 0.29, <i>p</i> &lt; 0.05) increased in the 2-year follow-up, indicating a relative escalating ocular burden compared with other muscle groups. A relative deceleration in MGOI change was observed between the second and the third follow-ups (in the second year). For MGOI-MGC, nonsteroid immunosuppressants (ΔMGOI-MGC: 0.20 ± 0.37, <i>p</i> &lt; 0.05) or prednisone treatment (ΔMGOI-MGC: 0.16 ± 0.35, <i>p</i> &lt; 0.05) were correlated with a more significant elevation. The long-term follow-up subcohort (0–4 years) validated the persistent increase in MGOI-ADL (0.18 ± 0.42, <i>p</i> &lt; 0.05) and MGOI-MGC (0.19 ± 0.37, <i>p</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion</h3>\u0000 \u0000 <p>Ocular symptoms are persistent in patients with MG, which might be related to the anatomical and physiological characteristics of extraocular muscles and their responsiveness to treatment.</p>\u0000 </section>\u0000 </div>","PeriodicalId":6939,"journal":{"name":"Acta Neurologica Scandinavica","volume":"2026 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ane/5560889","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147568590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Integrated Genetic, Molecular, and Imaging Machine Learning Model for Predicting Neurorepair Potential and Guiding Personalized Rehabilitation After Intracerebral Hemorrhage: A Multicenter Retrospective Study","authors":"Yixiao Cai,&nbsp;Xingzhi Liu,&nbsp;Jun Lei,&nbsp;Seidu A. Richard,&nbsp;Zhigang Lan,&nbsp;Xuangui Xie","doi":"10.1155/ane/4590863","DOIUrl":"https://doi.org/10.1155/ane/4590863","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Introduction&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Intracerebral hemorrhage (ICH) is a devastating subtype of stroke characterized by high mortality and disability rates.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Objective&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The objective of this study is to develop and validate a machine learning (ML) predictive model integrating genetic polymorphism, serum neurotrophic factor levels, and neuroimaging features for predicting 3-month spontaneous neurological recovery potential which is defined as favorable recovery with modified Rankin Scale (mRS) ≤ 2 without intensive rehabilitation intervention in patients with ICH and to explore its value in guiding personalized rehabilitation strategies.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A retrospective multicenter study was conducted in multiple tertiary hospitals. Baseline clinical data, brain-derived neurotrophic factor (BDNF) Val66Met gene polymorphism, serum BDNF and nerve growth factor (NGF) levels, and CT/MRI imaging features were collected. The mRS score at 3 months post-ICH was used as the primary outcome measure. Multiple ML algorithms, including logistic regression, random forest, and extreme gradient boosting (XGBoost), were applied to construct predictive models.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The XGBoost-based multidimensional model achieved the highest predictive efficacy, with an AUC of 0.892 (95% CI: 0.867–0.917) in the training cohort, 0.881 (95% CI: 0.848–0.914) in the internal validation cohort, and 0.875 (95% CI: 0.842–0.908) in the external validation cohort, significantly outperforming the conventional clinical model (AUC: 0.681, &lt;i&gt;p&lt;/i&gt; &lt; 0.001) and single-dimensional models (genetic model: AUC = 0.723; serum factor model: AUC = 0.756; imaging model: AUC = 0.782). DCA confirmed that the multidimensional model provided a higher net clinical benefit across a wide range of threshold probabilities. Stratification analysis revealed that patients with wild-type BDNF Val66Met genotype, high serum BDNF/NGF levels, and preserved white matter tract integrity had an 88.3% probability of favorable spontaneous recovery.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The multidimensional predictive model developed in this study demonstrates excellent performance in predicting 3-month neurological outcomes after ICH, which can effectively stratify patients into spontaneous recovery and intensive rehabilitation-required subgroups, providing a reliable basis for personalized post-ICH rehabilitation ","PeriodicalId":6939,"journal":{"name":"Acta Neurologica Scandinavica","volume":"2026 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ane/4590863","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147566973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Common and Disease-Specific EEG Microstate Alterations Across Alzheimer′s Disease, Parkinson′s Disease, Behavioral Variant Frontotemporal Dementia, and Multiple Sclerosis: A Cross-Disease Comparison","authors":"Shiyang Lv,&nbsp;Xiangying Ran,&nbsp;Huijing Xiang,&nbsp;Nian Wang,&nbsp;Zhengrong Zhou,&nbsp;Lei Chen","doi":"10.1155/ane/7974554","DOIUrl":"https://doi.org/10.1155/ane/7974554","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Alzheimer′s disease (AD), Parkinson′s disease (PD), behavioral variant frontotemporal dementia (bvFTD), and multiple sclerosis (MS) are common neurological disorders that disrupt brain networks and impair cognition and emotion. EEG microstates, as spatiotemporal markers of brain activity, have attracted increasing attention. They capture rapid large-scale brain dynamics on the millisecond timescale, offering a novel way to explore shared and distinct features across neurological disorders.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 123 participants were included in this study, 35 with AD, 18 with bvFTD, 16 with PD, 22 with MS, and 32 healthy controls (HCs). High-density EEG signals were recorded during eyes-closed resting state. EEG microstate analysis was performed to extract duration, occurrence, and coverage for each microstate class. Group differences were examined using one-way ANOVA or Kruskal–Wallis tests, as appropriate.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Compared with HC, patients with AD showed increased duration, occurrence, and coverage of Microstate C, and reduced occurrence and coverage of Microstate D. In PD, the duration of Microstate A was significantly reduced, whereas the occurrence and coverage of Microstate C were significantly elevated. The MS group showed partial differences relative to AD and PD, whereas no significant alterations were observed in bvFTD. Overall, Microstates C and D showed potential as cross-diagnostic electrophysiological biomarkers.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study identified disorder-specific microstate alterations, with the most prominent differences in Microstates C and D. Notably, the divergence in Microstate D between AD and PD may reflect distinct mechanisms of network disruption. These findings provide new insights into the network-level pathophysiology of neurological disorders and highlight the promise of EEG microstates as transdiagnostic biomarkers for characterizing large-scale functional impairments.</p>\u0000 </section>\u0000 </div>","PeriodicalId":6939,"journal":{"name":"Acta Neurologica Scandinavica","volume":"2026 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ane/7974554","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147564748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Next-Generation Genetic Testing in the Diagnostics of Neurological Disease in Southwest Finland in 2010–2021: A Register-Based Study","authors":"Saga Loukiainen,&nbsp;Maria K. Haanpää,&nbsp;Mika H. Martikainen","doi":"10.1155/ane/2203816","DOIUrl":"https://doi.org/10.1155/ane/2203816","url":null,"abstract":"<p>Neurological disorders are heterogeneous and sometimes challenging to diagnose. Next-generation sequencing (NGS) panels and exome sequencing methods are increasingly advocated as first-tier genetic investigations. In this retrospective, single-centre, register-based study, we investigated the use of NGS-based investigations in the diagnostics of adult neurological disease at Turku University Hospital (TUH) (Turku, Finland) during 2010–2021. We identified patients who underwent any genetic testing to investigate neurologic disease in 2010–2021. NGS gene panel studies and exome investigations were scrutinised further. Data were collected from the TUH electronic medical records. We identified <i>N</i> = 844 patients (347 men and 497 women) who fulfilled the initial inclusion criteria. In this group, 331 NGS panels and 99 exome analyses were performed. The median age at the time of the first included genetic test was 45 years (range: 16–96 years). The diagnostic rate was 19% for all NGS-based studies. Amongst different patient groups, the diagnostic yield was highest in developmental and intellectual disorders (39%), second highest in neuromuscular disorders (38%) and lower in epilepsy and ataxia (13% and 10%, respectively). Amongst neurological disorders, the diagnostic yield of genetic testing differs between different patient phenotypes and based on the genetic testing selection. Further studies are needed to determine optimal strategies, with the highest yield and lowest cost, for genetic investigations in neurological disorders.</p>","PeriodicalId":6939,"journal":{"name":"Acta Neurologica Scandinavica","volume":"2026 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ane/2203816","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147299968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Low-Intensity Ultrasound on Amyloid-β Clearance in Early-Stage Alzheimer′s Disease: A Potential Role of Glymphatic Activity","authors":"Sang Won Jo,&nbsp;Bo-yong Park,&nbsp;Roh-Eul Yoo,&nbsp;Seung Hong Choi,&nbsp;Sooyeon Ji,&nbsp;Tae Young Park,&nbsp;Hyungmin Kim,&nbsp;Seongbeom Park,&nbsp;Min Seung Kim,&nbsp;Suk Yun Kang,&nbsp;Soo-Jin Cho,&nbsp;Won-Jin Moon,&nbsp;SangYun Kim,&nbsp;Jaeho Kim","doi":"10.1155/ane/1538313","DOIUrl":"https://doi.org/10.1155/ane/1538313","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Alzheimer′s disease (AD) involves impaired clearance of metabolic waste, including amyloid-<i>β</i>, potentially related to glymphatic dysfunction. Low-intensity ultrasound (LIUS) may facilitate solute clearance in the brain. This pilot study examined whether LIUS affects amyloid-<i>β</i> deposition and cognitive performance in early-stage AD, and whether MRI-derived changes in putative glymphatic activity could represent a possible underlying mechanism.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This prospective pilot study (September 2022–February 2023) enrolled 10 amyloid-positive participants who underwent 4 weeks of LIUS treatment, including five apolipoprotein E4 (APOE4) carriers and five noncarriers. LIUS treatment involved sessions over 4 weeks. Magnetic resonance imaging (MRI) and amyloid PET scans were used to quantitatively analyze glymphatic activity, blood–brain barrier (BBB) integrity, microbleed occurrence, and amyloid deposition changes. Cognitive changes were assessed using neuropsychological tests.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>All participants completed treatment without any significant adverse events. Neuropsychological testing demonstrated cognitive function improvements. Amyloid-<i>β</i> deposition decreased mainly in APOE4 carriers following LIUS. In addition, post-LIUS, the cerebral cortex showed increased putative glymphatic activity, although statistical significance was not maintained after multiple-comparison correction. No significant changes were observed in BBB integrity, microbleed occurrence, or brain volume.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>LIUS was safe and demonstrated both cognitive improvement and reduced amyloid deposition in early-stage AD. These effects may reflect several biological actions of LIUS, including the possibility of glymphatic enhancement. Further studies with larger cohorts and appropriate control groups are warranted to confirm these findings and draw more definitive conclusions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>Clinicaltrial.gov identifier: NCT05633095</p>\u0000 </section>\u0000 </div>","PeriodicalId":6939,"journal":{"name":"Acta Neurologica Scandinavica","volume":"2026 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ane/1538313","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147315586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sensitivity and Specificity of Atropine Injection for Testing for Irreversible Loss of Brain Function: Experiences From 394 Examinations","authors":"Frank Logemann,&nbsp;Carl D. Reimers","doi":"10.1155/ane/2583072","DOIUrl":"https://doi.org/10.1155/ane/2583072","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Testing for brain death/death by neurologic criteria includes proof of irreversible loss of all brain functions. Intravenously administered atropine can serve as a complementary clinical test. This study determines the cut-off value, sensitivity, and specificity of the atropine test and examines implications for the safety of existing scientific guidelines.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A prospective multicenter observational study included patients who received atropine (2 mg intravenously) as part of an investigation for brain death/death by neurologic criteria. Data from brain death/death by neurologic criteria protocols, vital signs records, and diagnostic reports were collected in order to calculate the sensitivity and specificity of the atropine test per se and in comparison to the standard tests.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The study included 394 examinations in 257 patients (51.6 years, SD 16.3 years, 123 men, and 134 women) with suspected brain death/death by neurologic criteria.</p>\u0000 \u0000 <p>In brain-dead patients, there was no increase in heart rate above 10 bpm (i.e., specificity of 100% of a positive atropine test &gt; 10 bpm). Although of low sensitivity (17%) in proving residual brain function, the atropine test is twice as sensitive in revealing remaining brain functions as mandatory clinical tests (corneal, cough, and pupillary reflex <i>p</i> &lt; 0.05, apnea test and unresponsiveness to pain <i>p</i> &lt; 0.10).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>A cut-off value of 10 bpm achieves very good specificity, but only low sensitivity. However, the sensitivity of the atropine test was more than twice as high as that of all mandatory tests. Therefore, we suggest considering the simple atropine test in brain death/death by neurologic criteria diagnostics at least where brain perfusion investigations are not used.</p>\u0000 </section>\u0000 </div>","PeriodicalId":6939,"journal":{"name":"Acta Neurologica Scandinavica","volume":"2026 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ane/2583072","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146256419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stroke Code Transports by Emergency Medical Services: Positive Predictive Value and Therapeutic Decisions in a Large Finnish Province","authors":"Kristina Wikman,&nbsp;Tuukka Puolakka,&nbsp;Silja Räty,&nbsp;Markku Kuisma,&nbsp;Daniel Strbian","doi":"10.1155/ane/9677875","DOIUrl":"https://doi.org/10.1155/ane/9677875","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Precise prehospital identification of cerebrovascular diseases (CVD) is essential for timely decisions concerning recanalization therapy for acute ischemic stroke (IS). This study described the stroke chain by analyzing patients transported by emergency medical services (EMS) with a stroke code, focusing on the EMS process regarding both CVD recognition and final recanalization decisions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective, population-based, observational study analyzed all consecutive patients transported by EMS with suspected acute CVD in the Helsinki University Hospital service area during a 4-month period, irrespective of transport priority or receiving hospital. Prehospital and hospital patient records were combined, and the cohort was cross-checked with the database of given recanalization therapies. Sex-related and regional differences were assessed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Out of 1411 transports, 702 (50%) CVD diagnoses were identified. Of 521 high-priority transports, 317 (61%) received a CVD diagnosis and 98 (19%) recanalization therapy. Any recanalization therapy was given to 97/415 (23%) IS patients and to 91/211 (43%) IS patients transported with high priority. There were no significant sex-related or regional differences concerning diagnostic accuracy or treatment decisions. Altogether, 92% of the EMS transports ultimately leading to recanalization therapy were assigned high-priority stroke code.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The Finnish EMS system seems relatively accurate in identifying cerebrovascular disease; of all stroke-code transports, every second patient received a CVD diagnosis. Of the high-priority transports, 19% led to recanalization decisions. We observed no signs of gender or regional inequity. Most patients who received recanalization therapy were correctly identified by the EMS and transported with high priority, but this inevitably came at the expense of specificity.</p>\u0000 </section>\u0000 </div>","PeriodicalId":6939,"journal":{"name":"Acta Neurologica Scandinavica","volume":"2026 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ane/9677875","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146680335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overview and Research Trends on Cluster Headache Disease: A Bibliometric and Natural Language Processing Approach","authors":"Mohsen Hoseinnezhad,&nbsp;Mahdiyeh Khazaneha,&nbsp;Hamide Arvan,&nbsp;Mansoureh Togha","doi":"10.1155/ane/5110463","DOIUrl":"https://doi.org/10.1155/ane/5110463","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>This study presents a comprehensive analysis of the trends and challenges in cluster headache research from 1936 to 2022, highlighting the increasing study trend and the significant contributions from the United States, Italy, and England. The study identifies the most important journals, productive authors, and centers in the field, shedding light on the defects and challenges in pathophysiology, genetics, diagnosis, treatment, and study methods of cluster headaches.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Utilizing a bibliometric approach, the study examines the thematic and conceptual structural map, identifying key areas of focus in the pathophysiology, genetics, and neuroimaging studies of cluster headaches. The study also delves into the treatment phases and guidelines for cluster headaches, emphasizing the need for evidence-based and physiopathology-based treatment approaches.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The findings highlight the genetic and neuroimaging research gaps, the role of the hypothalamus, and the morphological alterations in the brain associated with cluster headaches. The study also discusses the limitations and challenges in the research and treatment of cluster headaches, emphasizing the need for improved clinical trial methodologies and treatment efficacy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The study concludes by underscoring the critical need for further research to address the limitations and challenges in understanding the pathophysiology, improving treatment efficacy, and enhancing the quality of life for individuals with cluster headaches. The study recommends future research with a comprehensive perspective to address the complexities and insufficiencies in the current understanding and treatment of cluster headaches.</p>\u0000 </section>\u0000 </div>","PeriodicalId":6939,"journal":{"name":"Acta Neurologica Scandinavica","volume":"2026 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ane/5110463","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146680327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Diagnostic Panel of Three Genetic Biomarkers Based on Artificial Neural Network for Patients With Idiopathic Generalized Epilepsy”","authors":"","doi":"10.1155/ane/9843676","DOIUrl":"https://doi.org/10.1155/ane/9843676","url":null,"abstract":"<p>A. Y. Tak, N. Tak, A. Bayrakoglu, et al., “Diagnostic Panel of Three Genetic Biomarkers Based on Artificial Neural Network for Patients With Idiopathic Generalized Epilepsy,” <i>Acta Neurologica Scandinavica</i>, 2024 (2024): 8853018, https://doi.org/10.1155/2024/8853018.</p><p>In the article, Alisan Bayrakoglu, Seda Susgun, and Ceyhun Toruntay were mistakenly omitted from the author list. The updated author list and affiliations are shown below and have been corrected in the article.</p><p>Ayşegül Yabacı Tak¹, Nihat Tak², Alisan Bayrakoglu³, Seda Susgun⁴, Ceyhun Toruntay⁵, Ferda Ilgen Uslu³, Emrah Yucesan⁶</p><p>1. Bezmialem Vakıf University, Faculty of Medicine, Department of Biostatistics and Medical Informatics, Istanbul, Türkiye</p><p>2. Marmara University, Faculty of Science, Department of Statistics, Istanbul, Türkiye</p><p>3. Bezmialem Vakıf University, Faculty of Medicine, Department of Neurology, Istanbul, Türkiye</p><p>4. Bezmialem Vakıf University, Faculty of Medicine, Department of Medical Biology, Istanbul, Türkiye</p><p>5. Istanbul Technical University, Faculty of Science and Letters, Department of Molecular Biology and Genetics, Istanbul, Türkiye</p><p>6. Istanbul Cerrahpaşa University, Institute of Neurological Sciences, Department of Neurogenetics, Istanbul, Türkiye</p><p>The author contributions are as follows:</p><p>Conceptualization: A.Y.T. and E.Y. Methodology: A.Y.T. and E.Y. Data curation: A.Y.T., N.T., S.S., C.T., F.I.U., and A.B. Formal analysis: A.Y.T. and N.T. Writing—original draft: A.Y.T., E.Y., and N.T. Writing—review and editing: A.Y.T., E.Y., and N.T. Visualization: A.Y.T. Supervision: A.Y.T.</p><p>We apologize for this error.</p>","PeriodicalId":6939,"journal":{"name":"Acta Neurologica Scandinavica","volume":"2026 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ane/9843676","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146193722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in Multiple Sclerosis Clinical Care and Outcomes During the COVID-19 Era: A Population-Wide Study","authors":"Giuseppina Affinito,&nbsp;Anna He,&nbsp;Fredrik Piehl,&nbsp;Katharina Fink,&nbsp;Raffaele Palladino,&nbsp;Jan Hillert,&nbsp;Kyla A. McKay","doi":"10.1155/ane/5580372","DOIUrl":"https://doi.org/10.1155/ane/5580372","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>The Coronavirus Disease 2019 (COVID-19) pandemic has had a profound impact on healthcare systems globally, necessitating significant adaptations in the management of chronic conditions such as multiple sclerosis (MS). In Sweden, where a unique approach to pandemic mitigation was adopted, the effects on MS clinical care remain a subject of interest. This population-based study is aimed at assessing changes in MS clinical care during the COVID-19 era compared to the prepandemic period.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Using the data from the Swedish MS Registry, encompassing the periods from January 29, 2018, to February 29, 2020 (pre-COVID-19 era), and from March 1, 2020, to April 1, 2022 (COVID-19 era), we analyzed MS incidence rates, clinic visits, relapse rates, initiation of disease-modifying treatments (DMTs), and dosing intervals for infusion medications. Statistical analyses, including interrupted time series and mixed Poisson regression models, were employed to assess changes in outcomes while adjusting for relevant covariates.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Our analysis included 19,959 MS patients. While there was a decrease in MS diagnoses during the pandemic period, this difference was not statistically significant. In contrast, a significant reduction in frequencies of physical clinical visits and relapse rates compared to the prepandemic period was evident. Treatment strategies shifted, with decreased utilization of anti-CD20 therapies and increased use of platform and other high-efficacy non–anti-CD20 DMTs. Dosing intervals for infusion medications were also extended during the COVID-19 era.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The findings underscore the substantial impact of the pandemic on MS clinical care practices and data capture in Sweden. Understanding these changes is crucial for monitoring or quality control of MS care, informing future research endeavors which access the Swedish MS Registry to measure disease outcomes in this population. The study highlights the responsiveness of healthcare systems in adapting to important challenges while emphasizing the importance of ongoing monitoring and adaptation in MS management practices.</p>\u0000 </section>\u0000 </div>","PeriodicalId":6939,"journal":{"name":"Acta Neurologica Scandinavica","volume":"2026 1","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/ane/5580372","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146099454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}